Sacituzumab biosimilar - Pinotbio
Alternative Names: PBX-001Latest Information Update: 30 Jun 2023
At a glance
- Originator Pinotbio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Dec 2021 Preclinical trials in Solid tumours in South Korea (Parenteral), prior to December 2021 (Pinotbio pipeline, December 2021)
- 31 Dec 2021 Pinotbio announces intention to submit IND for Solid tumours, at the end of 2025 (Pinotbio pipeline, December 2021)